Bright minds biosciences provides clinical program updates and outlines anticipated milestones for 2023

-- first-in-human phase 1 trial for lead program, bmb-101, a highly selective 5-ht2c agonist, is underway in australia -- -- company has transitioned from a discovery to a development organization –

DRUG Ratings Summary

DRUG Quant Ranking